drugset / Trial / NCT06541665

Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL

NCT06541665

Phase 1 Active not recruiting 20 enrolled Ono Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To confirm the tolerability and safety of combined administration of ONO-4059 and R-MPV therapy in untreated PCNSL patients.

Timeline

Start
2024-05-17
Primary completion
2028-04-28
Completion
2028-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirabrutinib Small molecule
Background Methotrexate Small molecule
Background Rituximab Monoclonal antibody
Background Vincristine Small molecule
Background procarbazine Small molecule